Yan Gao

Yan Gao

Auto-generated profile, based on publicly available information

Yan Gao

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
HBHuilian Bu
Huilian Bu
PJPengfei Jiao
Pengfei Jiao
XFXiaochong Fan
Xiaochong Fan
YGYan Gao
Yan Gao
LZLirong Zhang
Lirong Zhang
HGHaiming Guo
Haiming Guo
Huilian Bu, Pengfei Jiao, Xiaochong Fan, Yan Gao, Lirong Zhang, and Haiming Guo. Korean J Pain 2022;35:391-402. https://doi.org/10.3344/kjp.2022.35.4.391

11 February 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
CHCheng Huang
Cheng Huang
YLYi Li
Yi Li
HHHaixia He
Haixia He
YGYan Gao
Yan Gao
XZXu Zhang
Xu Zhang
HHHui-Qiang Huang
Hui-Qiang Huang
The aim of this study was to investigate the prognostic value of baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated with P-GEMOX regimen (pegaspargase, gemcitabine and oxaliplatin). A total of 97 patients were retrospectively evaluated. The relationships between baseline PETCT metabolic parameters and survival were tested using Cox regression analysis and receiver operating characteristic(ROC) curve analysis was employed to evaluate the optimal cut-off value of these parameters. Kaplan–Meier curves with log-rank tests were used for survival analysis. At a median follow-up of 49 months, the 3-year PFS and OS were 62.9% and 70.1%. SUVmean, SUVmax, and SUVpeak were related to both PFS and OS in univariate analysis(P < 0.05 for all). Further multivariate analysis including PET/CT parameters and clinical parameters revealed that SUVmean was an independent prognostic factor and seemed to be slightly superior to SUVmax and SUVpeak. The low SUVmean was significantly associated with a better prognosis (3-year OS 85.1% vs.65.0%, P = 0.014; 3-year PFS 76.8% vs.62.1%, P = 0.032). SUVmean was able to further separate patients with a low-risk PINK/PINKE of < 2(n = 85, 79, separately) into two subgroups with significantly different outcomes. Moreover, the metabolic-parameter-contained m-PINK/PINKE model was constructed and showed superior predictive performance in the whole cohort. Conclusions. SUVmean was an independent prognostic factor in patients with ENKTL treated with P-GEMOX chemotherapy. Adding SUVmean to the PINK or PINKE model could improve the predictive value and further distinguish patients with poor outcomes.